Zevra Therapeutics Q1 2025: Minimal Revenue, Significant Net Loss
Ticker: ZVRA · Form: 10-Q · Filed: May 13, 2025 · CIK: 1434647
| Field | Detail |
|---|---|
| Company | Zevra Therapeutics, Inc. (ZVRA) |
| Form Type | 10-Q |
| Filed Date | May 13, 2025 |
| Risk Level | high |
| Sentiment | bearish |
Sentiment: bearish
Topics: 10-Q, pharmaceuticals, financials, net-loss
TL;DR
Zevra Therapeutics Q1 2025: $1.5K revenue, $53.7M expenses, $54.7M cash. Still burning cash.
AI Summary
Zevra Therapeutics, Inc. reported its first quarter 2025 results ending March 31, 2025. The company had minimal revenue of $1,528 for the quarter, a decrease from $1,615 in the prior year period. Operating expenses were $53.7 million, leading to a net loss. The company's cash and cash equivalents stood at $54.7 million as of March 31, 2025.
Why It Matters
This filing details Zevra Therapeutics' financial performance in early 2025, highlighting their operational costs and revenue generation, which is crucial for investors assessing the company's viability and future prospects.
Risk Assessment
Risk Level: high — The company reported a significant net loss and minimal revenue, indicating a high burn rate and reliance on future funding or product success.
Key Numbers
- $1,528 — Revenue (Revenue for the three months ended March 31, 2025, showing minimal sales.)
- $53,670,709 — Net Loss (Net loss for the three months ended March 31, 2025, indicating significant operational costs.)
- $54,679,363 — Cash and Cash Equivalents (Liquidity position as of March 31, 2025.)
- 10,000,000 — Common Stock (Authorized shares of common stock.)
- 250,000,000 — Preferred Stock (Authorized shares of preferred stock.)
Key Players & Entities
- Zevra Therapeutics, Inc. (company) — Filer of the 10-Q report.
- March 31, 2025 (date) — End of the reporting period for the 10-Q.
- $1,528 (dollar_amount) — Revenue for the three months ended March 31, 2025.
- $53,670,709 (dollar_amount) — Net loss for the three months ended March 31, 2025.
- $54,679,363 (dollar_amount) — Cash and cash equivalents as of March 31, 2025.
- Neil F. McFarlane (person) — President and Chief Executive Officer.
- Adrian W. Quartel (person) — Chief Medical Officer.
- R. LaDuane Clifton (person) — Chief Financial Officer and Treasurer.
- Joshua Schafer (person) — Chief Commercial Officer.
FAQ
What was Zevra Therapeutics' revenue for the first quarter of 2025?
Zevra Therapeutics reported revenue of $1,528 for the three months ended March 31, 2025.
What was the net loss for Zevra Therapeutics in Q1 2025?
The company reported a net loss of $53,670,709 for the three months ended March 31, 2025.
How much cash and cash equivalents did Zevra Therapeutics have at the end of Q1 2025?
As of March 31, 2025, Zevra Therapeutics had $54,679,363 in cash and cash equivalents.
What is the authorized number of common stock shares for Zevra Therapeutics?
Zevra Therapeutics has 10,000,000 shares of common stock authorized.
Who are the key executive officers listed in the filing?
The key executive officers listed are Neil F. McFarlane (President and CEO), Adrian W. Quartel (Chief Medical Officer), R. LaDuane Clifton (Chief Financial Officer and Treasurer), and Joshua Schafer (Chief Commercial Officer).
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 13, 2025 by Neil F. McFarlane regarding ZEVRA THERAPEUTICS, INC. (ZVRA).